HomeNewslettersHepatic Cell NewsAZGP1 Activation by Lenvatinib Suppresses Intrahepatic Cholangiocarcinoma Epithelial-Mesenchymal Transition Through the TGF-β1/Smad3...
Scientists found that AZGP1 was the key target of lenvatinib in intrahepatic cholangiocarcinoma (ICC), and its low expression in ICC cancer tissues was associated with a poor prognosis in patients.